LMC’s telemedicine service is dedicated to the provision of medical consultation and follow-up services for Diabetes & Endocrine conditions to individuals over the age of 18 living in the various LHIN’s. We have recently begun accepting referrals from...
Sanofi announced on July 28th that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The...
Collaboration Brings Together Leading U.S. Metabolism-Focused CRO and Largest Canadian Diabetes Site Network SAN DIEGO AND TORONTO, June 10, 2016 /PRNewswire/ – Profil Institute for Clinical Research, a science-driven clinical research organization (CRO) focused...
